InVivo Therapeutics Announces Publication in *Neurosurgery* of Case Report Detailing First *Neuro-Spinal Scaffold™* Implantation


Dr. Theodore said, “I am gratified that the case report detailing the safety and feasibility of the implantation of the *Neuro-Spinal Scaffold* was published in a distinguished journal. The patient’s improvement to date has been notable and provides the basis for my continued enthusiasm for the INSPIRE study.”

“We are very pleased to have the first clinical *Neuro-Spinal Scaffold* case report published in a leading, peer-reviewed neurosurgical journal,” Mark Perrin, InVivo’s CEO and Chairman, said. “We have been steadily increasing awareness in the neurosurgical community and look forward to additional publications on the INSPIRE study.”

The publication is now available electronically through *Neurosurgery* prior to print publication at:

[http://journals.lww.com/neurosurgery/Abstract/publishahead/First_Human_Implantation_of_a_Bioresorbable.97328.aspx](http://journals.lww.com/neurosurgery/Abstract/publishahead/First_Human_Implantation_of_a_Bioresorbable.97328.aspx)

About The INSPIRE Study

The **INSPIRE** Study: InVivo Study of Probable Benefit of the *Neuro-Spinal Scaffold* for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and probable benefit of the *Neuro-Spinal Scaffold* for the treatment of complete T2-T12/L1 spinal cord injury in support of a Humanitarian Device Exemption (HDE) application for approval. For more information, refer to [https://clinicaltrials.gov/ct2/show/study/NCT02138110](https://clinicaltrials.gov/ct2/show/study/NCT02138110).
About the **Neuro-Spinal Scaffold™** Implant

Following acute spinal cord injury, surgical implantation of the biodegradable **Neuro-Spinal Scaffold** within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The **Neuro-Spinal Scaffold**, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

**About InVivo Therapeutics**

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational **Neuro-Spinal Scaffold** received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit [www.invivotherapeutics.com](http://www.invivotherapeutics.com).

**Safe Harbor Statement**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold and future publications. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the impact of achieving the OPC on the FDA approval process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

###